News

HDA Media And Political Bulletin – 4 October 2016

ABPI WELCOMES CHANCELLOR’S PLEDGE TO SUPPORT PHARMA INDUSTRY

3 October 2016, Pharmacy Business, Neil Trainis

 

Phillip Hammond, the Chancellor of the Exchequer, announced at the Conservative Party Conference that the Government plan to invest £220 million into the life sciences sector in the UK. He has also pledged that the Pharmaceutical Industry will be supported with subsidies following Brexit.  The Chancellor explained that bidders who secure multi-year funding from the European Union before the UK exits will receive Government subsidies after Brexit. The UK will leave the EU by the summer of 2019 if Prime Minister Theresa may triggers Article 50 at the end of march next year. Mike Thompson, Chief Executive of the ABPI said that the announcements by Phillip Hammond are excellent news for the industry and that the Government are sending a clear signal that the UK remains open for business.

 

This story was also reported by the ABPI here and further comment was made by the ABPI here. It was also reported by The Pharma Times here.

 

ABPI statement in response to NICE proposed fees to assess new medicines

2 October 2016, ABPI, Paul Catchpole

 

NICE has unveiled plans to charge fees of up to £282,000 for the assessment of a new medicine. Dr Paul Catchpole, Value and Access Director, ABPI, said that although NICE is facing significant budgetary pressures, there are considerable efficiency savings that could be made in order to prevent the need to charge for services. He believes that since the proposed fee is the highest flat- fee ever proposed by a health technology assessment organisation it may prevent smaller companies from launching new medicines. Thereby these plans have the potential to create further inequalities in access to medicines for NHS patients.

 

Parliamentary Coverage

 

There is no parliamentary coverage today.

 

Full Coverage

ABPI WELCOMES CHANCELLOR’S PLEDGE TO SUPPORT PHARMA INDUSTRY

3 October 2016, Pharmacy Business, Neil Trainis

The Association of the British Pharmaceutical Industry has welcomed Philip Hammond’s pledge to invest £220 million in the life sciences sector and continue to support the UK pharmaceutical industry with subsidies after Brexit.

The Chancellor (pictured) told the Conservative conference in Birmingham that bidders who secure multi-year European Union funding for projects before the UK leaves the EU will see those initiatives benefit from UK government subsidies after Brexit.

The UK will leave the EU by the summer of 2019 if it triggers Article 50 of the Lisbon Treaty by the end of March next year as the Prime Minister Theresa May has said.

Hammond’s pledge came after he promised the government would spend £220 million on new technology in the life sciences sector and university research.

“Both announcements from Philip Hammond are excellent news and demonstrate that the government wishes to build on the UK’s existing strengths and prioritise the businesses and structures that support British science and innovation. This will not only be important for the economy, but absolutely vital for the NHS and UK patients,” said Mike Thompson, chief executive of the ABPI.

“What we hear is a clear signal from government that the UK remains open for business, and will continue to be a great place for the discovery and development of the medicines and medical technologies of the future.

“As the country moves forward and forges a new relationship with the rest of the world, we must to continue to invest in innovation – and the success and stature of the UK pharmaceutical industry is no better example of how that investment can pay off.”

 

ABPI statement in response to NICE proposed fees to assess new medicines

2 October 2016, ABPI, Paul Catchpole

Responding to the news that NICE will charge fees of up to £282,000 to assess a new medicine, Dr Paul Catchpole, Value & Access Director, ABPI, said;

“NICE is facing significant budgetary pressures whilst the demands being placed on its work programmes are increasing, but we believe that there are considerable efficiency savings that could be me made to its current appraisal processes which would either eliminate the need to charge for services or reduce the amount that has to be charged.

NICE processes also need to evolve so they are fit to properly appraise the new medicines being produced by the pharmaceutical industry and this should happen before they consider charging.   The proposed flat-fee charges are the highest ever seen from any health technology assessment organisation in the world and the cost will be prohibitive for smaller companies and will also pose challenges for all companies in creating compelling business cases for launching medicines for smaller populations and for rarer diseases in the UK.

This has the potential to create further inequalities in access to medicines for NHS patients”.

HDA Media And Political Bulletin – 4 October 2016

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?